KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016 - 2025)

CRISPR Therapeutics AG's Gains from Sales and Divestitures history spans 10 years, with the latest figure at $736238.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 63.35% year-over-year to $736238.0; the TTM value through Dec 2025 reached $736238.0, up 63.35%, while the annual FY2025 figure was $736238.0, 63.35% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $736238.0 at CRISPR Therapeutics AG, up from $590587.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $736238.0 in Q4 2025 and bottomed at $109355.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $272278.5 (2023), against an average of $309757.3.
  • The largest annual shift saw Gains from Sales and Divestitures surged 2087.1% in 2021 before it plummeted 47.76% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $455440.0 in 2021, then tumbled by 47.76% to $237932.0 in 2022, then increased by 16.76% to $277808.0 in 2023, then skyrocketed by 62.23% to $450701.0 in 2024, then skyrocketed by 63.35% to $736238.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Gains from Sales and Divestitures are $736238.0 (Q4 2025), $590587.0 (Q3 2025), and $501884.0 (Q2 2025).